Identifying magnetic resonance imaging (MRI) markers in myelin-oligodendrocytes-glycoprotein antibody-associated disease (MOGAD), neuromyelitis optica spectrum disorder-aquaporin-4 positive (NMOSD-AQP4) and multiple sclerosis (MS) is essential for establishing objective outcome measures.
Contrasting the brain imaging features of MOG-antibody disease, with AQP4-antibody NMOSD and multiple sclerosis
Calabrese, Massimiliano;
2022-01-01
Abstract
Identifying magnetic resonance imaging (MRI) markers in myelin-oligodendrocytes-glycoprotein antibody-associated disease (MOGAD), neuromyelitis optica spectrum disorder-aquaporin-4 positive (NMOSD-AQP4) and multiple sclerosis (MS) is essential for establishing objective outcome measures.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
13524585211018987.pdf
accesso aperto
Descrizione: CC BY-NC 4.0 publisher version
Tipologia:
Versione dell'editore
Licenza:
Creative commons
Dimensione
797.19 kB
Formato
Adobe PDF
|
797.19 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
